GSK-163090
- Generic Name
- GSK-163090
Patient Tolerability Study of GSK163090
Phase 1
Completed
- Conditions
- Depressive Disorder, MajorMajor Depressive Disorder (MDD)
- First Posted Date
- 2007-11-16
- Last Posted Date
- 2012-03-19
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 20
- Registration Number
- NCT00559299
- Locations
- 🇺🇸
GSK Investigational Site, Wichita, Kansas, United States
Study Of Safety, Blood Levels, And Brain Receptor Occupancy Of GSK163090 Using PET Imaging In Healthy Males
Phase 1
Completed
- Conditions
- Healthy SubjectsDepressive Disorder and Anxiety Disorders
- Interventions
- First Posted Date
- 2007-02-15
- Last Posted Date
- 2012-06-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 13
- Registration Number
- NCT00435695
- Locations
- 🇨🇦
GSK Investigational Site, Toronto, Ontario, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath